Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith S Currier

Showing results (221-230 of 298) with videos related to

Pageof 30
Sort By:
The Journal of Infectious Diseases|January 20, 2023
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19Babafemi O Taiwo, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|August 31, 2023
Variant-Specific Viral Kinetics in Acute COVID-19Ruy M Ribeiro, Manish C Choudhary, Rinki Deo, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Steven K Grinspoon, Kathleen V Fitch, Edgar Turner Overton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2015
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2025
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2Steven K Grinspoon, Sophia Zhao, Esteban Martinez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 2, 2015
Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy InitiationRupak Shivakoti, Wei-Teng Yang, Nikhil Gupte, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|July 19, 2024
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical TrialKara W Chew, Babafemi O Taiwo, Carlee Moser, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, et al.
JACC. Advances|May 15, 2025
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE SubstudyMichael T Lu, Heather J Ribaudo, Sara McCallum, et al.
Pageof 30

Showing results (221-230 of 298) with videos related to

Sort By:
Pageof 30
The Journal of Infectious Diseases|January 20, 2023
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19Babafemi O Taiwo, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|August 31, 2023
Variant-Specific Viral Kinetics in Acute COVID-19Ruy M Ribeiro, Manish C Choudhary, Rinki Deo, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Steven K Grinspoon, Kathleen V Fitch, Edgar Turner Overton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2015
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2025
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2Steven K Grinspoon, Sophia Zhao, Esteban Martinez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 2, 2015
Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy InitiationRupak Shivakoti, Wei-Teng Yang, Nikhil Gupte, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|July 19, 2024
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical TrialKara W Chew, Babafemi O Taiwo, Carlee Moser, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, et al.
JACC. Advances|May 15, 2025
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE SubstudyMichael T Lu, Heather J Ribaudo, Sara McCallum, et al.
Pageof 30